SAB Biotherapeutics, Inc.
SABSW- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001833214
No open-market purchases or sales by SAB Biotherapeutics, Inc. insiders were filed in the last 90 days; 8 institutions reported holding it in 13F filings for Q2 2026, worth $10.5K in total; no superinvestor holds it.
Other share classesSABS
Q3 2025 vs. Q2 2025
How the institutions holding SAB Biotherapeutics, Inc. changed between Q2 2025 and Q3 2025.
All holders in Q3 2025All holders in Q2 2025
| Measure | Q2 2025 | Of which not filed for Q3 2025 | Q3 2025 | Change |
|---|---|---|---|---|
| Holders | 6 | 1 | 10 | +5 |
| Shares | 802.4K | 78.8K | 829.5K | +105.9K (+14.6%) |
| Value | $26.7K | $2.63K | $19.5K | −$4.56K (−18.9%) |
1 institution that held it in Q2 2025 haven't filed for Q3 2025 yet. Not filing isn't selling, so the changes leave them out.
New holders (5)
Institutions that held SAB Biotherapeutics, Inc. at the end of Q3 2025 but not at the end of Q2 2025.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Clear Street Group Inc. | 79,033 | $1.85K | 0.00% |
| Susquehanna International Group, LLP | 26,302 | $750 | 0.00% |
| UBS Group AG | 23,414 | $539 | 0.00% |
| Bank of America Corp | 200 | $5 | 0.00% |
| Toronto Dominion Bank | 200 | $5 | 0.00% |
Sold out (0)
Institutions that held SAB Biotherapeutics, Inc. at the end of Q2 2025 and filed for Q3 2025 without it.
None.
Not filed for Q3 2025 yet (1)
Institutions that held SAB Biotherapeutics, Inc. at the end of Q2 2025 and haven't filed a 13F for Q3 2025. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q2 2025 | Value, Q2 2025 |
|---|---|---|
| Clear Street LLC | 78,833 | $2.63K |